logo

Cerus Corp (CERS)



Trade CERS now with
  Date
  Headline
11/7/2017 8:34:50 AM Cerus Corp. Receives IDE Approval To Initiate Phase III ReCePI Study
10/30/2017 8:37:57 AM Cerus Reports Agreement With Transfusion Center Of The Community Of Madrid
10/5/2017 8:33:02 AM Cerus Unveils First Biologics License Application Approval For U.S. Blood Center Customer
8/2/2017 8:31:45 AM Cerus Corp. Enters Into $40 Mln Amended Growth Capital Agreement
5/15/2017 8:42:44 AM First Patient Transfused In Cerus’ Phase III RedeS Study Evaluating Efficacy Of INTERCEPT Red Blood Cell System
3/7/2017 4:01:58 PM Cerus Corp Q4 Loss/share $0.13 Vs. Loss $0.15 Year Ago
10/13/2016 8:38:22 AM Cerus Says First U.S. Blood Center Customer Submits BLA To Allow For Interstate Export Of INTERCEPT Platelet Components
8/29/2016 8:34:53 AM FDA's New Recommendation For Universal Zika Risk Reduction Of Blood Components Includes Use Of Pathogen Reduction
11/8/2012 7:57:41 AM Robert W. Baird Is Increasing Cerus Corp (CERS) FY12 Estimate To -0.35 From -0.36
8/3/2012 8:14:35 AM Robert W. Baird Reiterates Cerus Corp (CERS) At Outperform With $6 Price Target
8/3/2012 7:32:29 AM Robert W. Baird Is Raising Cerus Corp (CERS) FY12 Estimate To -0.36 From -0.40
5/2/2012 7:59:49 AM Robert W. Baird Reiterates Cerus Corp (CERS) At Outperform With $6 Price Target
5/2/2012 7:49:05 AM Robert W. Baird Is Lowering Cerus Corp (CERS) FY12 Estimate To -0.40 From -0.32
2/29/2012 9:38:42 AM Robert W. Baird Is Lowering Cerus Corp (CERS) FY12 Estimate To -0.32 From -0.30
2/29/2012 9:21:15 AM Robert W. Baird Upgrades Cerus Corp (CERS) To Outperform From Neutral With $6 up from $3 Price Target